Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Ofatumumab showed a consistent and long-term reduction in relapse rates and T2 lesion activity in patients with recently diagnosed, treatment-naïve relapsing multiple sclerosis.

Ofatumumab Demonstrates Sustained Efficacy in Recently Diagnosed and Treatment-Naive Relapsing Multiple Sclerosis Over 5 Years

An analysis of a phase 3 trial of low sodium oxybate in patients with idiopathic hypersomnia identified a minimal clinically important difference in the visual analog scale for sleep inertia.

Analysis of Low-sodium Oxybate Proposes Minimal Clinically Important Difference in Visual Analog Scale for Sleep Inertia 

Videos

The associate professor of neurology at University of California, San Francisco talked about findings from an analysis that assessed the safety of ocrelizumab when administered close to pregnancy. [WATCH TIME: 5 minutes]

Pregnancy Outcomes of Maternal Exposure to Ocrelizumab: Riley Bove, MD

A phase 3b study showed that switching from intravenous C5 inhibitors to subcutaneous zilucoplan in patients with myasthenia gravis was associated with symptom improvement at 12 weeks.

Switching to Subcutaneous Zilucoplan Raises No Safety Concerns in Myasthenia Gravis

The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]

Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhD

Director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital.

The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]

New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD

, has been with the team since September 2022. Follow her on Twitter 

The executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.

NeuroVoices: Sharon Hesterlee, PhD, on Givinostat’s Approval for Duchenne Muscular Dystrophy, Future Prospects

Manager of Health Literacy at National MS Society.

Elizabeth Miller, MA, the manager of health literacy at the National MS Society, discussed the impact of health literacy in the multiple sclerosis community. 

Advancing Equity and Inclusion: Health Literacy for the MS Community and Beyond

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Abigail Paras, BS

Articles